Acadian Asset Management LLC Has $1.41 Million Stock Holdings in Humana Inc. (NYSE:HUM)

Acadian Asset Management LLC trimmed its position in Humana Inc. (NYSE:HUM) by 11.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,773 shares of the insurance provider’s stock after selling 506 shares during the quarter. Acadian Asset Management LLC’s holdings in Humana were worth $1,409,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CarsonAllaria Wealth Management Ltd. grew its holdings in Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after buying an additional 39 shares in the last quarter. Hantz Financial Services Inc. acquired a new position in Humana in the 2nd quarter valued at $35,000. Family Firm Inc. acquired a new position in Humana in the 2nd quarter valued at $37,000. Riverview Trust Co bought a new stake in shares of Humana during the 2nd quarter valued at $44,000. Finally, Carolinas Wealth Consulting LLC lifted its position in shares of Humana by 274.1% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock valued at $46,000 after acquiring an additional 74 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Down 0.9 %

Shares of NYSE:HUM opened at $321.56 on Monday. Humana Inc. has a 52-week low of $298.61 and a 52-week high of $530.54. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The business’s 50 day simple moving average is $364.11 and its two-hundred day simple moving average is $346.85. The firm has a market cap of $38.72 billion, a P/E ratio of 20.02, a PEG ratio of 2.56 and a beta of 0.50.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter last year, the company earned $8.94 earnings per share. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. As a group, research analysts forecast that Humana Inc. will post 16 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.10%. Humana’s dividend payout ratio is presently 22.04%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on HUM shares. Bank of America upped their target price on Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a research report on Monday, May 20th. Deutsche Bank Aktiengesellschaft upped their target price on Humana from $341.00 to $349.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. Piper Sandler assumed coverage on Humana in a research report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 price objective for the company. Baird R W raised Humana to a “hold” rating in a report on Thursday, May 30th. Finally, Oppenheimer increased their price target on Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. Thirteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $398.70.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.